Wilmington, DE -- (SBWIRE) -- 12/23/2013 -- -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) and Sanofi (NASDAQ:GCVRZ).
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) a company that together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States is currently down (-2.47%) on 1,702,344 shares traded. Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) is currently down (-43.67%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)
Sanofi (NASDAQ:GCVRZ) a global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products is currently up (+18.67%) on 4,543,857 shares traded. Sanofi (NASDAQ:GCVRZ) is currently up (+102.17%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Sanofi (NASDAQ:GCVRZ)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report